Log in

Opthea Stock Forecast, Price & News

-0.15 (-1.14 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $13.06
50-Day Range N/A
52-Week Range
Now: $13.06
Volume37,887 shs
Average Volume80,771 shs
Market Capitalization$551.24 million
P/E RatioN/A
Dividend YieldN/A
Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 4.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.72 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:OPT
Phone61 3 9826 0399



Sales & Book Value

Annual SalesN/A



Market Cap$551.24 million
Next Earnings DateN/A
OptionableNot Optionable
-0.15 (-1.14 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Opthea (NASDAQ:OPT) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Opthea?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opthea in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Opthea
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Opthea?

Wall Street analysts have given Opthea a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Opthea wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for OPT?

6 brokerages have issued 1 year price objectives for Opthea's stock. Their forecasts range from $25.00 to $48.00. On average, they expect Opthea's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 175.7% from the stock's current price.
View analysts' price targets for Opthea

Who are Opthea's key executives?

Opthea's management team includes the following people:
  • Dr. Megan Baldwin M.A.I.C.D., Ph.D., MAICD, MD, CEO & Exec. Director (Age 45)
  • Mr. Michael Tonroe B.Sc., F.C.A., M.A.I.C.D., Bsc(Hons), ACA, MAICD, CFO & Company Sec. (Age 53)
  • Ms. Annie Lee, Fin. & Operations Mang.
  • Dr. Richard Chadwick, Head of Intellectual Property (Age 54)
  • Dr. Michael Gerometta, Head of Chemistry, Manufacturing & Controls Devel. (Age 56)
  • Dr. Ian Leitch, Director of Clinical Research
  • Dr. James Goding, Independent Consultant

When did Opthea IPO?

(OPT) raised $161 million in an IPO on Friday, October 16th 2020. The company issued 9,300,000 shares at $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers.

What is Opthea's stock symbol?

Opthea trades on the NASDAQ under the ticker symbol "OPT."

When did the company's quiet period expire?

Opthea's quiet period expired on Wednesday, November 25th. Opthea had issued 8,563,300 shares in its initial public offering on October 16th. The total size of the offering was $115,604,550 based on an initial share price of $13.50. During the company's quiet period, insiders and underwriters involved in the IPO were restricted from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Opthea?

Shares of OPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Opthea's stock price today?

One share of OPT stock can currently be purchased for approximately $13.06.

How big of a company is Opthea?

Opthea has a market capitalization of $551.24 million.

What is Opthea's official website?

The official website for Opthea is www.opthea.com.

How can I contact Opthea?

The company can be reached via phone at 61 3 9826 0399.

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.